试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-26
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
编号:NCT04120883登记状态:提前终止企业 / 申办者:University of Michigan
药物 / 成分:Hydroxychloroquine lower dose、Hydroxychloroquine higher dose
登记的停止原因(原文):Unable to recruit additional participants after multiple extensions to planned enrollment period.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-26
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
编号:NCT04627675登记状态:提前终止企业 / 申办者:Providence Health & Services
药物 / 成分:CORVax、IL-12 plasmid、Cliniporator
登记的停止原因(原文):Study was ended prematurely due to lack of efficacy. As per FDA guidance, our site continued to follow enrolled subjects through the 180 day safety visit.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-26
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
编号:NCT04771299登记状态:提前终止企业 / 申办者:Lakshmi N Yatham
药物 / 成分:Cariprazine、Placebo
登记的停止原因(原文):Research support no longer available.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-26
Lefamulin for M. Genitalium Treatment Failures
编号:NCT05111002登记状态:提前终止企业 / 申办者:University of Washington
药物 / 成分:Lefamulin、Doxycycline
登记的停止原因(原文):At Sponsor Request
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-26
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
编号:NCT05289492登记状态:提前终止企业 / 申办者:iTeos Therapeutics
药物 / 成分:EOS884448、Iberdomide、Dexamethasone
登记的停止原因(原文):Company operational decision. Decision to stop study is not due to safety or efficacy concerns
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-24
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
编号:NCT03311126登记状态:提前终止企业 / 申办者:University of Wisconsin, Madison
药物 / 成分:Bendamustine、Obinutuzumab
登记的停止原因(原文):slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-24
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
编号:NCT04358458登记状态:提前终止企业 / 申办者:Genmab
药物 / 成分:GEN3009、Epcoritamab
登记的停止原因(原文):Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-24
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
编号:NCT04513158登记状态:提前终止企业 / 申办者:Joseph M. Flynn, D.O., MPH
药物 / 成分:Convalescent Plasma
登记的停止原因(原文):Newly reported data at the time indicated that alternative therapies were more effective than CP for early treatment of high-risk patients with COVID-19.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-24
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
编号:NCT04690699登记状态:提前终止企业 / 申办者:Istari Oncology, Inc.
药物 / 成分:Lerapolturev、5% DDM
登记的停止原因(原文):business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-23
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
编号:NCT02118584登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Etrolizumab
登记的停止原因(原文):The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.
查看官方原始记录 ↗